Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
SWOG Cancer Research Network
OHSU Knight Cancer Institute
Medical College of Wisconsin
Ascentage Pharma Group Inc.
Bristol-Myers Squibb
Gruppo Italiano Malattie EMatologiche dell'Adulto
Mansoura University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Teva Branded Pharmaceutical Products R&D, Inc.
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
University of Glasgow
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
University of Bologna